Transcatheter arterial chemoembolization and radiofrequency ablation in a joint venture with immunotherapy for hepatocellular carcinoma patients

Keywords
immunotherapy, hepatocellular carcinoma, radiofrequency ablation, Transcatheter arterial chemoembolization

Abstract
Successive current trials using immune response checkpoint blockade, the systemic therapy for progressive hepatocellular carcinoma (HCC) has shifted dramatically towards targeting the tumor microenvironment (TME). Locoregional therapies (LRTs) like radiofrequency ablation (RFA)/rhizotomy, trans-arterial chemoembolization (TACE) and surgical resection in the initial stages are critical. LRTs perform the crucial task of modulating the immune system surrounding the tumor, which is of great importance in the prevailing era of developing immuno-oncology treatments and their direct effect on tumor cells. Significant efforts are needed in exploring the mechanisms of latest combinational approach to boost clinical advantage with tolerable side effects. The present review highlights the tumor microenvironment of HCC followed by current immunotherapeutic approaches for HCC. Next, we discussed the concealed mechanisms of LRTs given in combination with immunotherapy and their utilization in clinical practice.

Explanation letter
Review 1:
Please indicate which databases were used in the preparation of this review.
N/A
Response: We are grateful to the reviewer for reading our manuscript and his/her positive comment as well as appreciating our work.

Review 2:
well written but needs more information.
Authors are suggested to see the following papers and integrate them to the current review.
Response: We are thankful to the reviewer for suggesting such nice studies. We have cited all the above mention studies in our revised manuscript and highlighted them with yellow colour.

Review 3:
The present manuscript "Transcatheter arterial chemoembolization and radiofrequency ablation in a joint venture with immunotherapy for hepatocellular
carcinoma patients" can be accepted in its present form.
Response: We are grateful to the reviewer for reading our manuscript and his/her positive comment as well as appreciating our work.

Section Editor recommendation
I recommend accept this manuscript after one more minor revision suggested by the reviewer.
Response: We are thankful to the editorial board for considering our manuscript as well as their positive comments. We have revised the manuscript following the reviewer comments. We believe that the revised manuscript is now suitable for publication.
Response letter 28012022.docx
Transcatheter arterial chemoembolization and radiofrequency ablation in a joint venture with immunotherapy for hepatocellular carcinoma patients

Liang Wang¹,#, Zhong-Qiang Yu¹,#, Ke-Lin Yao¹, Jing-Song Hu¹, Shao Gao¹, Lv-Cong Zhu¹, Rui-Ming Xia¹*

¹Department of Radiology, the Affiliated Hospital of Shaoxing University (Shaoxing Municipal Hospital), Shaoxing 312000, Zhejiang Province, P.R. China

#, These authors contributed equally to this work.

* Corresponding author:
Dr. Rui-Ming Xia, the Affiliated Hospital of Shaoxing University (Shaoxing Municipal Hospital), 999 Zhongxing South Road, Shaoxing 312000, Zhejiang Province, P.R. China. Tel: +86-0575-88293701, Fax: +86-0575-88293113, Email: xiaruim@163.com
Abstract
Successive current trials using immune response checkpoint blockade, the systemic therapy for progressive hepatocellular carcinoma (HCC) has shifted dramatically towards targeting the tumor microenvironment (TME). Locoregional therapies (LRTs) like radiofrequency ablation (RFA)/rhizotomy, trans-arterial chemoembolization (TACE) and surgical resection in the initial stages are critical. LRTs perform the crucial task of modulating the immune system surrounding the tumor, which is of great importance in the prevailing era of developing immuno-oncology treatments and their direct effect on tumor cells. Significant efforts are needed in exploring the mechanisms of latest combinational approach to boost clinical advantage with tolerable side effects. The present review highlights the tumor microenvironment of HCC followed by current immunotherapeutic approaches for HCC. Next, we discussed the concealed mechanisms of LRTs given in combination with immunotherapy and their utilization in clinical practice.

Keywords: hepatocellular carcinoma, Transcatheter arterial chemoembolization, radiofrequency ablation, immunotherapy.
Introduction

One of the most familiar liver diseases is Hepatocellular carcinoma (HCC) and it is the third leading cause of death among all types of cancers [1, 2]. Treatment options available from Locoregional therapies (LRTs) for a localized tumor to systemic treatments for metastatic HCC or multifocal carcinoma, depending on the nature of the disease. Three LRTs, i.e., trans-arterial chemoembolization (TACE), radiofrequency ablation (RFA) and cryoablation, are recommended in patients whose immune system rejects liver transplant or surgical resection. However, most patients ultimately develop a refractory disease that needs systemic treatment [3]. Currently, the only FDA approved systemic drug is sorafenib. Regorafenib [4], ramucirumab [5], cabozantinib [6], and Lenvatinib are examples of targeted treatment that have shown efficacy in first-line and second-line treatment in HCC and are certified by FDA. On the other hand, programmed cell death protein-1 (PD-1 inhibitors) such as pembrolizumab and nivolumab has achieved approval by FDA only in the second-line environment [7, 8]. Providing the proven efficacy of each treatment option in HCC, the conclusive debate is whether it is reasonable to continue the immunotherapy and TACE combination, or the moderate effect of immunotherapy can be transferred to the adjuvant setting post-TACE in the advanced setting. The current review highlights the tumor microenvironment of HCC followed by current immunotherapeutic approaches for HCC. Next, we discussed the concealed mechanisms of LRTs given in combination with immunotherapy and their utilization in clinical practice.

IMMUNE LANDSCAPE OF HCC
The liver is often inflamed as an outcome of chronic hepatitis infection or long-term liver injury [9]. However, mild inflammation acts as a barrier against pathogens and helps to heal tissue injury, whereas persistent liver inflammation may disrupt the microenvironment and aggravate carcinogenesis [10-12]. The liver may generate inflammatory mediators like chemokines and cytokines, which accelerate angiogenesis, anti-apoptotic cascades, and immune evasion as well as attract immunocytes capable of creating a niche microenvironment that promotes tumor development [13-15]. Tumor-linked chemokines and cytokines can engage and polarise immune molecules into a tumor supporting phenotype, thereby promoting tumor development. Tumor-associated macrophages are polarised into M2 macrophage by IL-4, IL-10, IL-13, and TGF-b exist in the TME and initiate development of tumor by recruiting CD4+FoxP3+ regulatory T-cells (Tregs) (Figure 1) and stimulating angiogenesis, are one such immune subset [16, 17]. TAM accumulation in the tumor region is linked to a weak diagnosis in various cancers, including HCC [16, 18].

Tregs, which control or dampen the cytotoxic potential and activate CD8-positive T cells, act as an integral component in tumorigenesis [19, 20]. Earlier, we stated that Tregs from HBV-positive hepatocellular carcinoma has shown an increased expression of PD-1 and were more effective at suppressing CD8-positive T cells. Tregs production by higher intra-tumoral interleukin-17 has been regularly identified in HCC patients, linked to a worse prognosis and shorter survival [12, 18, 19, 21, 22]. TGF-b-rich HCC TME also promotes Th17 separation, a CD4+ T subgroup also produces IL-17 [23]. In HCC patients, high intra-tumoral Th17 frequencies were linked to microvascular invasion and weak overall survival rate (OS) along with disease-free survival (DFS) [24].
CD4+ T helper 1 cells (Th1) can produce IFN-g, on the other hand, can activate dendritic cells, resulting in improved excitation and advancement of CD8+ T cells [25, 26]. Helper cells Th1 also activates dendritic cells-mediated tumor suppression via IFN-g-dependent pathways, fueling anti-tumor immune responses downstream (Figure 1) [27]. Patients with HCC are treated with transarterial chemoembolization (TACE), an improvement in Th1 response was linked to better outcomes [28]. Though Th1 has demonstrated anti-tumor activity, compared to the normal healthy livers, type 2 CD4+ T helper cells (Th2) cells were augmented in HCC tissues and are conversely related with overall survival of HCC patients [29]. Th2-type cytokines like interleukin-10 (IL-10), interleukin-4 (IL-4) and interleukin-13 (IL-13) will make M2 macrophages less cytotoxic, reducing CD8+ T cell-initiated cytotoxic activity (Figure 1) [30, 31]. Moreover, increased Th2 cytokine output has been associated with an enhanced risk of HCV-HCC [32, 33].

Immune molecules that are cytotoxic, like natural killer cells (NK), CD8+ T effector memory (Tem) and CD8+ T resident memory (Trm) act as an anti-tumor agent [18, 21]. However, natural killer cells around the HCC tumor regions were found to have lower cytolytic ability and IFN-g output than NK cells from a healthy cellular environment [34]. Lee Y.H. states that the Tregs obtained from HCC patients has shown a reduction in the tumor-suppressing capacity of homologous NK cells (Figure 1). Although the existence of Tem and Trm cells can be a bridge for a better prediction in HCC [35], they frequently release biomarkers including lymphocyte-activation gene 3 (LAG-3), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and PD-1 that are adversely linked with a functional ability (Figure 1) [36, 37]. As a result, these fatigue markers have been ICB's primary targets for reinvigorating and restoring CD8 T cells' cytotoxic ability [38]. The detailed landscape of HCC is shown in Figure 1.
Figure 1. The immune system episodes contribute to a favorable or unfavorable mechanism in HCC. CD4+ T helper 2 (Th2) cell enrichment is linked to a weak overall survival rate in patients with HCC. TGF-b and Th2- generates cytokines like IL-4, IL-10, and IL-13, that promote tumor-linked macrophages (TAMs) to polarise into M2 macrophage phenotype as an immunosuppressive agent that attracts T regulatory cells (Tregs). Particularly, Tregs improve the immunosuppressive tumour surrounding environment by blocking the pathway of natural killer cells and CD8+ T memory/effector cells that possess tumor-killing capability that weaken disease prognosis. TGF-b also assisted in CD4+ T helper 17 (Th17) cell differentiation and increased Th17 cell prevalence are linked to enhanced microvascular aggression and decreased DFS and OS in patients with HCC. Since CD4+ T helper 1 cells (Th1) can enhance CD8+ T cell excitation with the help of dendritic cells (DC) and stimulate DC-mediated tumor-suppression, their presence was linked to better outcomes in HCC. Despite their ability to destroy tumour cells and their connection to a better prognosis in HCC, upregulation of fatigue biomarkers is shown by CD8+ T cells (e.g., LAG-3, PD-1 and CTLA-4), inhibiting their killing potential in chronic conditions and leading to tumor progression. Reproduced with permission from [39].
**Immunotherapy in HCC (Immune Checkpoint blockers)**

PD-1 inhibitors like nivolumab and pembrolizumab in second-line treatment have shown their recent involvement in mature and metastatic HCC after sorafenib. Pembrolizumab and nivolumab were approved by FDA after conducting two different clinical trials, the Keynote-224 on 105 patients and Checkmate 040 on 262 patients, respectively [40, 41]. Both the trials were Phase II stage single arm and open-label experiments on patients with metastatic HCC resistant to sorafenib. Patients with Child Pugh A score were included in both trials. However, patients with B7 were included in Checkmate 040 regardless of hepatitis B or C. Pembrolizumab had a 17 percent overall objective response rate and nivolumab had a 20 percent overall unbiased response rate with greater number of responding patients receiving long-term responses. Without considering whether the patients had infectious hepatitis or not, the therapy was well accepted. Program Cell Death Ligand 1 (PD-L1) expression did not appear to be related to nivolumab response. Although phase III staged placebo-controlled trial (Keynote-240) in second-line treatment found that pembrolizumab reduced the risk of death by 20%, it fell short of its statistical goals [42].

In the front-line environment, the findings of a recently published randomized phase III clinical trial (Checkmate 459) distinguishing nivolumab and sorafenib did not meet the previously stated statistical relevance for overall survival (OS), i.e., (HR 0.84, P = 0.0419), despite significant improvements in OS (16.4mo vs 14.7mo), ORR (15 percent vs 7%) and CR (4 vs 1) with nivolumab. PD-L1 negative and positive tumors showed responses. 22% registered against nivolumab related side effects; however, 49% have reported side effects against sorafenib [43]. Other checkpoint inhibitors of immune cells have shown minimal activity in progressed HCC. PD-L1 antibody durvalumab has shown 10% overall response in pre-treated HCC patients [44].
Whereas Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a tremelimumab antibody that has shown 17 percent response, equivalent to PD-L1 or PD-1 inhibitors, but only in a limited population of 20 patients who rejected the options of surgery or LRTs in chronic hepatitis C and progressed HCC [45]. PD-L1 negative and positive tumors showed responses. 22% registered against nivolumab related side effects; however, 49% have reported side effects against sorafenib [44]. In the HIMALAYA Phase 3 trial, identical tremelimumab and durvalumab were distinguished from sorafenib in the first-line treatment [46].

Anti- PD-L1/PD-L1 or Anti-CTLA-4 antibodies were combined with alternative approaches such as anti-angiogenesis in a number of ongoing trials. In the most recent study named as IMbrave150, the combined effect of bevacizumab and atezolizumab (anti-PD-L1), has shown targeted response on vascular endothelial growth factor A (VEGF-A), an approach that has shown the dominant effect in improving progression-free survival (PFS) and OS in comparison to first-line treatment with sorafenib. The average effect of bevacizumab and atezolizumab combination on OS was not achieved after 8.6 months of median follow-up as seen with to sorafenib for 13.2 months (95 percent CI, 0.42–0.79; hazard ratio [HR] 0.58; p = 0.0006), however with the combination the median PFS was found to be 6.8 months, whereas with sorafenib PFS was 4.5 months (95 percent CI, HR 0.59) There were continuous adverse episodes about safety chart of all the drugs separately as well as in combination regimen [47].

In conclusion, immune checkpoint inhibitors, when taken as a single agent, has shown average response in second-line setting against HCC followed by sorafenib, whereas the combinational effect has demonstrated that anti-angiogenesis is leading to the front-line treatment setting due to its promising potential results.

Local Ablation technique and Immune regulation
Local ablation technique is now advised as one of the best efficient treatment options available for early-stage HCC. Microwave ablation (MWA) and radiofrequency ablation (RFA) are the two most frequent used thermal/energy-based ablation modalities. Introduction of energy and high temperature into the tumour, the combo together can trigger inflammatory signaling molecules, stimulate tumour necrosis and produce neoantigens, leading to anti-tumor effects [48, 49]. Cryoablation (Cryo), unlike heat-based thermal ablation, causes cell inflammation by freezing tumour cells [50]. Another non-thermal ablation method is irreversible electroporation (IRE). Inducing milliseconds of electrical pulses results in increased permeability of cell membrane and ultimately cell apoptosis, as opposed to the thermal modality. Furthermore, it does little damage to the extracellular environment, preserving the tissues and structural constituents in their entirety [51]. The secretion of a cytokine known as macrophage migration inhibitory factor (MIF) that stimulates immune cells is the most significant effect of immunological IRE compared to RFA after the HCC procedure [52]. The mechanisms by which ablation can modulate immunity are as follows.

**Delivery of Tumor-Affiliated Antigen**

Tumor necrosis caused by ablation can result in cross-presentation, TAA release, and dendritic cells (DCs) recruitment. Antigen related cellular immunity to T cells may be stimulated by inflammatory cytokines secreted from the local microenvironment [53]. TAA is a requirement for immune response. Intracellular components, including highly immunogenic proteins like heat shock protein 70 (HSP-70) are released when a tumour is destroyed; therefore, it stimulates antigen-presenting cells (APCs), inducing an antitumor immune reaction through MHC-1 signaling pathway [54]. A specific epitope of alpha-fetoprotein (AFP) can also stimulate mild-to-
moderate CD8+ T response in peripheral blood mononuclear cells (PBMCs) [55]. The imbalance of pro- and anti-inflammatory molecules in these disorders implies that treatment efforts aimed at suppressing excessive inflammation may benefit in disease recovery [56].

**Changing the Level of Cytokine Expression**

Ablation/abscission elicits an intense immunological response on the edge of the local region. In fact, due to the need for liver homeostasis, tissue can initiate the self-mending process. Macrophages present at the wound site can secrete local cytokines [57]. Ablation helps to boost the immunostimulating proteins expression of like Tumour necrosis factor-alpha (TNF-α), interferons (IFN), interleukins (IL-1, IL-2) meanwhile silencing immunosuppressive proteins like hepatocyte growth factor (HGF) and soluble IL-2 receptor. It also increases the expression of CD4+/CD8+ ratio by provoking natural killer (NK) cells, CD3+ T/CD4+ T cells and lymphokine-activated killer cells (LAK) to become more active [58, 59].

**Motivating the Immune mechanism of Lymphocytes**

After peripheral blood ablation, significant increase in movement of CD3+T/CD4+ T cells was observed. The ratio of CD45RO+, CD3+, CD68+ and CD56+ cells in the local tumor region also improves, which can last up to 30 days [60]. The effects of cytotoxic T lymphocytes (CTLs) on locally situated tumors and the immune responses are enhanced by aggregation of tumor-infiltrating lymphocytes (TILs) and circulating peripheral lymphocytes. Nevertheless, ablation can assist tumor growth, particularly after incomplete ablation process. Ablation can also trigger cell proliferation in HCC by upregulating the IL-L6, VEGF, HIF-1, and PD-1 expressions [61, 62].
a result, it is worth paying more attention to the resources to conduct expanded research on combinational ablation and immunotherapy.

**Radiation therapy and ICIs**

Immunoregulation necessitates the presence of RT. It causes tumor cells to release neoantigens, stimulates naive T-cell differentiation and proliferation, and improves T-cell functioning when given together with a PD-1 inhibitor [63]. Since the introduction of immunomodulators, radiation-induced abscopal effects had gained enough in preclinical models [64-66]. In an animal experiment, Kim et al. show that EBRT upregulates PD-L1 expression through the IFN-γ and STAT3 signaling cascades, supporting anti-PD-L1 therapy. Therefore, this combination extended the mice's survival (P 0.001) when compared to radiotherapy or anti-PD-L1 therapy alone [67]. Another study by Yoshimoto et al. revealed that RT, along with anti-CTLA-4 would boost antitumor effects of immune system and prolong tumor development duration in a mouse model, which was found to be from 13.1 to 19.5 days [68]. Because of its accurate radiation delivery to the targeted lesions with less damage to the surrounding healthy tissue, selective internal radiotherapy (SIRT) is now a more acceptable option in HCC treatment [69]. Transcatheter arterial radioembolization (TARE) uses the hepatic artery to deliver radioactive particles to the target tumour, becoming a stable internal radioactive source. 131I-labeled iodized oil and 90Y microspheres are among the radioactive materials [70]. The immunocompetence of the TME has been confirmed to improve after 90Y therapy. This is due to increased TNF-expression on CD8+ T and CD4+ cell surface and an improvement in the ratio of APCs [71]. Figure 2 shows the various Locoregional therapies and immunomodulation.
Figure 2. After peripheral blood ablation, the activity of CD3+T/CD4+ T cell increases abruptly. The population of CD3+, CD45RO+, CD56+, and CD68+ cells in the local tumour increases, which can last up to 30 days. The effects of cytotoxic T lymphocytes (CTLs) on local tumors and the immune responses are enhanced by tumor-infiltrating lymphocytes (TILs) aggregation and circulating peripheral lymphocytes. On the other hand, ablation has the potential to initiate tumor growth, particularly after the incomplete ablation process. Hepatocellular carcinoma locoregional therapy immunomodulation mechanism. EBRT, TACE, or brachytherapy can be responsible for the cell death of local tumour and release immunogenic proteins like ATP and HSP70 and TAA, which initiate APC and introduce antigens through the MHC-I pathway. Meanwhile, it attracts dendritic cells to the growing tumours and amplifies costimulatory signaling molecules, allowing tumor-specific T cells to enter the blood circulation and promoting the anti-tumor effect of CTL. Treg undergoes infiltration from local tumour tissue and spreads to distant in non-treated lesions, causing them to regress. Locoregional therapy alters cytokine expression and TME, which modulates tumour immunity. Simultaneously, LRT can cause immunosuppressive agents to produce (IL-6, HIF-1, TGF-β, PD-1, Tregs, and so on) that promote tumour progression. The combination of locoregional and immunotherapy is thought to be promising. Tumor-associated antigens (TAA), effector T cells (Teffs), cytotoxic T lymphocyte (CTL), tumor microenvironment (TME), antigen-presenting cell (APC), regulatory T cells (Tregs), major histocompatibility complex-I (MHC-I), major histocompatibility complex II (MHC-II), programmed cell death protein 1 (PD-1), T cell receptor (TCR), cytotoxic T lymphocyte–associated protein 4 (CTLA-4), high-mobility group protein (HMGB1), vascular cell adhesion molecule-1 (VCAM-1),...
immunogenic cell death (ICD), transforming growth factor-β (TGF-β), transcatheter arterial chemoembolization (TACE), interferon-γ (IFN-γ), hypoxia-inducible factor-1α (HIF-1α), interleukin-2 (IL-2), interleukin-6 (IL-6), heat shock protein 70 (HSP70). Reproduced with permission from [72].

**TACE and Immunomodulation**

Transcatheter arterial chemoembolization (TACE) is a popular technique for irresistible HCC with a reserved liver function that may possess immune system regulating properties. After occlusion of feeding arteries, TACE can cause local tumour necrosis and release tumour-specific antigens secured by APCs and trigger tumor-specific immune responses. TACE has also been shown to alter the cytokine spectrum, T cell activity levels, and immune cell subsets [73, 74]. It increases IFN- and IL-1 secretion while suppressing IL-10 expression. It may also increase the expression of T helper 17 cells (Th17). In patients with low Treg cells expression, TACE can shift the tumour microenvironment (TME) to Th1 dominance resulting in a better prognosis [75]. As compared to pre-TACE levels, CD4+ and CD25+ Tregs in the peripheral blood decreased dramatically (7.58 to 2.65 percent, P=0.05), whereas the ratio of CD4+ to CD8+ increases significantly (30.52 4.19 vs 1.29 0.14) [76]. However, TACE can also manage to accelerate histanoxia, leading to an increase in expression of PD-L1, HIF-1α and aggregation of Tregs ultimately resulting in immunological tolerance at last. For this reason, the disease prognosis of patients been subjected to TACE is largely based on the stability of tumor immune rescue and anti-tumor immunity [75, 77]. TACE damages the bile ducts and liver (figure 3). Hence, it is crucial to conduct curative TACE when the tumor is localized and controllable. Arachidonic acid and other polyunsaturated fatty acids in combination with immune check point inhibitors and tumour infiltrating lymphocytes enhance the activity of T, NK, and macrophages, thereby assisting in tumour cell elimination and suppressing inflammatory side effects associated with immune check point inhibitors[78].
**Figure 3:** Showing the negative impact of TACE. Reproduce with permission from [79].

**TACE Combined with ICIs**
TACE begins to necrotise the tumour by blocking the way of the tumor's nourishing artery, triggering a tumor-specific immune response, and secreting neoplastic antigens. Meanwhile, it promotes anoxia, which increases the release of immunosuppressive agents (Tregs, PD-1, and MDSCs) and immune resistance [80]. As a result, tumours may become immune-tolerant after one-time TACE treatment. TACE and ICIs together can improve the overall anti-tumor response. A CTLA-4 inhibitor tremelimumab and TACE have shown safety and affordability in a pilot study of HCC patients [45]. A dose of 15mg/kg of tremelimumab for 90 days before tumour progression or extreme toxicity, was given intravenously in the study. The result provides an acceptable safety
profile and none of the patients needed steroids for any serious immune initiated adverse effects. After the first dose, some patients encountered a temporary but serious increase in transaminases, and it did not occur in consecutive cycles. The limited response rate was found to be 17.6%, disease management was found to be 76.4 percent, and duration of development was 6.48 months (95% confidence interval: 3.95–9.14) [45, 81].

Tremelimumab was administered to HCC patients already receiving sorafenib in other clinical trials. Six doses of tremelimumab in four weeks was prescribed, followed by intravenous administrations every three months till the patient reached off-treatment criteria. DEB-TACE was given to patients on day 35 (drug-eluting bead TACE). At 2, 6, and 14 months, CT scans were performed. After 6 months the primary lesion shrank and nearly vanished, while the lesions of the non-treated intrahepatic region shrank gradually [82] One case at our centre, was a 47-year-old male patient with Child-Pugh Class A of HCC was treated with a combination of a recombinant humanised monoclonal anti-VEGF antibody (IBI305) and a fully humanised Ig 4 anti-PD-1 monoclonal antibody (sintilimab Tyvyt®), both are certified for clinical trial by the National Medical Products Administration (NMPA) of China (Certificate No.: The patient had been treated five times with TACE in the eight months following his diagnosis. The patient agreed to take combinational therapy of IBI305 and sintilimab with TACE after the primary lesions shrank partly and new lesions appeared. Zhang et al. reported that the new combination of locoregional ablation and allogeneic cell adoption was safe and showed promising clinical effectiveness against HCC and ICC [83].

Intravenous administration of IBI305 and Sintilimab were given at a three-week gap at a dose of 900 mg and 200 mg each, for a total of five doses. Tracking the progression of lesions was performed every 6 weeks and the patient was taken to contrast-enhanced CT scans (one scan
performed after every 2 doses). The total area of different lesions was reduced significantly when observed in CT images, involving that partial reduction was attained steadily right before the death endpoint. The case had shown a beneficial primary outcome when IBI305 and sintilimab were given in combination with TACE to cure HCC. Another experiment conducted with nivolumab in patients with progressed HCC (NCT 03143270) is presently undergoing a phase I trial combined with DEB-TACE. The aim of this study is to look for the safest combination therapy at various stages. Up to one year, all participants will be treated with intravenous nivolumab (240 mg) every two weeks. TACE along with nivolumab is also studied in phase II staged single-arm trial it is an open-label study for intermediate-staged HCC (NCT 03572582), which concentrates on the degree of response. Initially TACE treatment will be distributed into cycles of 4-week. Day 1 (four days) of cycle 3 (eight weeks and four days later), the following TACE will be repeated. Locoregional therapy can stimulate the preparation of expression of Th17 and T cells in the peripheral circulation by provoking the immunostimulating agents (IFN-, TNF-α) simultaneously inhibits immunosuppressive factors (IL-6). Irradiation treatment shrinks vessel density and expands cytotoxic T lymphocyte permeability in the vascular system. It also increases the expression of VCAM-1 and promotes cytotoxic T cell infiltration, which boosts the anti-tumor immune response. There are currently numerous clinical trials ongoing or completed that use TACE and radio-frequency ablation in a joint venture with immunotherapy for hepatocellular carcinoma patients (Table 1).

<table>
<thead>
<tr>
<th>Therapies</th>
<th>Immunotherapeutic drugs or agents</th>
<th>Clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>TACE</td>
<td>Pembrolizumab</td>
<td>NCT03397654</td>
</tr>
<tr>
<td>#</td>
<td>Procedure</td>
<td>Treatment</td>
</tr>
<tr>
<td>---</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>2</td>
<td>TACE</td>
<td>Immuncell-LC</td>
</tr>
<tr>
<td>3</td>
<td>TACE</td>
<td>Durvalumab also Bevacizumab</td>
</tr>
<tr>
<td>4</td>
<td>TACE</td>
<td>Immune checkpoint inhibitor</td>
</tr>
<tr>
<td>5</td>
<td>TACE</td>
<td>Nivolumab or pembrolizumab</td>
</tr>
<tr>
<td>6</td>
<td>TACE</td>
<td>DC-CIK</td>
</tr>
<tr>
<td>7</td>
<td>TACE</td>
<td>CTAL-4/PD-L1 (Durvalumab and Tremelimumab)</td>
</tr>
<tr>
<td>8</td>
<td>TACE</td>
<td>Autologous Tcm Immunotherapy</td>
</tr>
<tr>
<td>9</td>
<td>TACE</td>
<td>Nivolumab</td>
</tr>
<tr>
<td>10</td>
<td>TACE</td>
<td>Immune Killer cells</td>
</tr>
<tr>
<td>11</td>
<td>TACE</td>
<td>Cytokine-Induced Killer (CIK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chemoembolization (TACE) or Ablation (RFA)</td>
</tr>
<tr>
<td>12</td>
<td>Y90-Radioembolization</td>
<td>Nivolumab</td>
</tr>
<tr>
<td>13</td>
<td>Ablation</td>
<td>Nivolumab</td>
</tr>
<tr>
<td>14</td>
<td>Y90-Radioembolization</td>
<td>Pembrolizumab</td>
</tr>
</tbody>
</table>

**Table 1.** Selected ongoing clinical trials of using TACE and radio-frequency ablation in a joint venture with immunotherapy for hepatocellular carcinoma patients [https://www.clinicaltrials.gov/].
FUTURISTIC APPROACH USING COMBINATIONAL REGIMEN FOR HCC

Apart from using ICB and RT in HCC therapy, the phase III staged trial of IMbrave150 in patients of HCC has displayed the upper hand in OS, PFS and ORR when treated with anti-VEGF-A bevacizumab and anti-PD-L1 atezolizumab as compared to the patients gone through sorafenib treatment [84]. Angiogenesis is the major hallmark of cancer, a crucial component in tumour development and progression and has been a promising target for drug evaluation in HCC [35, 85, 86]. The vascular abnormalities seen in HCC tumors have been linked to dysregulated VEGF expression [86, 87]. The outcome of other research experiments in HCC patients has demonstrated increased levels of VEGF after RFA or surgery is directly linked to a weak prognosis [88, 89]. Shigeta et al. explained the underlying pathway of the combinational treatment of anti-VEGF-A and anti-PD-L1 against tumor genesis using an orthotopic murine HCC model. They found that inhibiting VEGFR2- alone shows increased PD-1 levels on CD4+ cells in tumor; however, when given in combination with anti-PD-1 therapy, the functioning of CD4+ cells was restored, leading to normal vessel formation. The combined therapy also enhances cytotoxic CD8+ T cell activation and tumor infiltration while Treg and monocyte infiltration decreases [90].

The expression level of VEGF in RT treated HCC tumors was significantly elevated [89]. Depending on this, it is worthwhile to investigate the potency of treating HCC patients with ICB and anti-angiogenesis after RT because of their capability to strengthen tumor-killing activities and control the tumor cells to renew (Figure 4). A second strategy is using an anti-angiogenic drug before RT to “normalise” tumour vasculature and, as a result, increase the efficacy of the radiotherapy effects [91]. Following this combination treatment, ICB could be given to maintain anti-tumor immunity (Figure 4). Anti-angiogenics are linked to serious toxicity to gastrointestinal
as a result of enhanced exposure to RT; therefore, careful evaluation of such treatment is required [92]. Other acceptable combinations like dual RT with ICBs can be looked at as well.

**Figure 4.** The hypothesis of combining immune checkpoint blockade, anti-angiogenesis agents and radiotherapy in a single treatment. The key role of immunomodulation of all the therapeutic agents, as well as the synergetic effect of their combination in HCC, are depicted in the diagram. Immune infiltrates into TME are increased by RT, and amplification of immune checkpoint agents (e.g., CTLA-4, PD-L1 and PD-1) and VEGF are shown. Anti-VEGF accelerates normal vessel formation, which raises RT potency and/or increases cytotoxic cell infiltration into TME and improves CD4+ T cell PD-1 levels. The synergistic role of ICB and RT improves the effect of anti-
VEGF and RT therapies by restoring and further enhancing anti-tumor immune responses. Reproduced with permission from [39].

**Conclusion and Future Perspective**

Evidence from the studies states that LRTs have better immune modulation properties in HCC patients, which strongly suggests the potential and synergistic effect of combined treatment with immune checkpoint blockers should be investigated in depth. However, many unanswered questions pop up regarding LRTs: when is the best time to start immunotherapy; before, during, or after? What biomarkers are the most effective at predicting response to this combination? Is there a connection between PD-L1 status and response? Can immunotherapy induce substantial immune activation in early/locally advanced HCC to produce similar results? Any of these questions can be answered by ongoing research and multidisciplinary collaboration.

**Acknowledgement**

This work was supported by the Program from the Health and Family Planning Commission of Zhejiang Province (No. 2019KY727 to ZQY) and the Program of Science and Technology (Medical and Health) from Shaoxing (No.2018C30032 to LW).

**Conflict of interest**

All the author declare that they have no conflict of interest to declare.

**References**


43. **An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma.** 01-03-2021; Available from: https://www.smartpatients.com/trials/NCT02576509.


53. Keisari, Y., **Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation.** Front Biosci (Landmark Ed), 2017. **22:** p. 310-347.


84. Cheng, A.L., et al., LBA3 - IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atez) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Annals of Oncology, 2019. 30: p. ix186-ix187.


